


● Phase 2b: placebo/dupilumab ● Phase 2b: dupilumab/dupilumab
 ● QUEST: placebo/dupilumab ● QUEST: dupilumab/dupilumab


(A) High-dose ICS at PSBL



Number of patients

Phase 2b PBO/DPL	52	52	50	52	51	52	52		50		49	49	49
Phase 2b DPL/DPL	193	193	190	190	189	188	186		184		175	175	177
QUEST PBO/DPL	232	232	224	227	222	225	227		223		103	102	102
QUEST DPL/DPL	414	413	395	396	390	399	389		381		188	185	187

(B) Medium-dose ICS at PSBL



Number of patients

Phase 2b PBO/DPL	46	46	46	46	46	46	45		43		44	42	42
Phase 2b DPL/DPL	152	152	149	152	148	151	148		143		139	137	138
QUEST PBO/DPL	190	189	184	186	172	182	182		177		83	81	82
QUEST DPL/DPL	387	385	378	376	367	370	375		364		173	174	175